NTLA Q4 2017 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+18.5% YoY

Gross Profit

-$15M-217.5% margin

Operating Income

-$25M-370.7% margin

Net Income

-$24M-359.4% margin

EPS (Diluted)

$-0.61

QoQ Revenue Growth

-8.9%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$24M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$376M

Total Liabilities

$76M

Stockholders' Equity

$301M

Cash & Equivalents

$341M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$6M	+18.5%
Gross Profit	-$15M	-$6M	-154.2%
Operating Income	-$25M	-$11M	-128.4%
Net Income	-$24M	-$11M	-126.9%